anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Basaglar
Trial phase: Phase 3
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 220
Group description: Participants received insulin glargine administered QD SC. The starting dose of insulin glargine was 6 IU/day at bedtime, titrated to a FBG between 72-100 mg/dL, following a TTT algorithm.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months
Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use [≤14 consecutive days] for acute conditions)
HbA1c ≥7.5% to ≤11.0% at screening
Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
Body mass Index (BMI) ≥23 kilograms per meter squared

Exclusion Criteria:

Type 1 diabetes mellitus
Have history of chronic or acute pancreatitis
Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
Have a history of ketoacidosis or hyperosmolar state/coma
Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility
Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months
Intervention: Naltrexone
Trial phase: Phase 4
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 179
Group description: The intervention is multimodal and consists of:

Intramuscular injections of 380mg extended-release Naltrexone, given once monthly for 3 months.
Case Management services

Extended Release Naltrexone: Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
Eligibility criteria:
Inclusion Criteria:

Active alcohol use by self-report
Known alcohol use disorder or suspected alcohol use disorder and Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 or AUDIT-C score > 4, or frequent emergency department visits and hazardous drinking defined as: At least 3 emergency department visits in the past 12 months, including the index visit, and Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 or AUDIT-C score > 4

Exclusion Criteria:

Opioid use: currently receiving opioid analgesics, self-report of opioid use in past 7 days, current physiologic opioid dependence, patients in acute opioid withdrawal, urine toxicology screen positive for opiates including fentanyl
History of hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, or any other components of the diluent
Liver function tests (AST, ALT) > 5x upper limit of normal or known cirrhosis
Platelets less than 100,000 per cubic mm
Acute condition at the time of enrollment that necessitates medical therapy with opioids
Pregnant
Incarcerated
Intervention: Sertraline
Trial phase: Phase 4
ATC code: N06AB06
SMILES: CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table

Sertraline: daily SSRI (Sertraline 25mg)
Eligibility criteria:
Inclusion criteria:

18 years of age or older
Documentation of confirmed HIV-1 infection
Six to eight weeks postpartum
Currently taking ART treatment
Able and willing to provide written informed consent
Willing to adhere to study visit schedule
PND diagnosis confirmed by Mini-International Neuropsychiatric Interview

Exclusion criteria:

Taking an ADM in the prior 12 months prior to enrollment
Actively suicidal
Known or suspected allergy or contraindication to first line Sertraline
Any other condition (social or medical) which, in the opinion of the study staff, would make trial participation unsafe or complicate data interpretation.
Intervention: Ampreloxetine
Trial phase: Phase 3
SMILES: Fc1cc(F)c(OCc2ccccc2C2CCNCC2)c(F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: Participants received a single dose of 10 mg ampreloxetine QD for a planned duration of up to 182 weeks.
Eligibility criteria:
Inclusion Criteria:

Completion of Study 0170 and, in the opinion of the Investigator, would benefit from long-term treatment with ampreloxetine.
The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject's current therapeutic regimen).
The subject must be willing to continue on treatment and must continue to meet all the inclusion criteria for the preceding study (Study 0170) except, a score of >4 in OHSA#1.

Exclusion Criteria:

Subjects may not be enrolled in another clinical trial.
Psychiatric, neurological, or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant.
Hypersensitivity to ampreloxetine or the formulation excipients.
Intervention: Humulene
Trial phase: Phase 2
SMILES: CC1=CCCC(C)=CCC(C)(C)C=CC1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 1
Group description: In this session, the participant will smoke two-thirds of one cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.

Cannabis: Smoked active cannabis (7% THC)
Eligibility criteria:
Inclusion Criteria:

Males/non-pregnant females
Report smoking cannabis ≥1 day per week
Able to perform all study procedures

Exclusion Criteria:

Meeting DSM-V criteria for severe substance use
Use of illicit drugs ≥1 day/week in the prior 4 weeks
Abnormality with the eyes which may affect the eye tracking technology such as color blindness, naturally occurring nystagmus, amblyopia, strabismus, age-related macular degeneration (AMD), cataract, diabetic eye disease, glaucoma, dry eye, extreme refractive error, bacterial or viral infections of the eye
7. User of supplemental oxygen
Intervention: Semaglutide
Trial phase: Phase 3
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 133
Group description: Participants received once weekly s.c. injection of semaglutide for 68 weeks. Participants initially received 0.25 mg of semaglutide and the dose was then escalated once in 4 weeks for 16 weeks until the target dose of 2.4 mg was reached which was maintained for a period of 52 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 12), 1.7 mg (week 13 to week 16) and 2.4 mg (week 17 to week 68). The treatment was an adjunct to a reduced-calorie diet and increased physical activity.
Eligibility criteria:
Inclusion Criteria:

Informed consent of parent(s) or legally acceptable representative of subject and child assent, as appropriate obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
Male or female, ages 12 to below 18 years at the time of signing informed consent
BMI equal to or above 95th percentile OR equal to or above 85th percentile (on gender and age-specific growth charts (CDC.gov)) with 1 or more weight related comorbidity (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes
History of at least one self-reported unsuccessful dietary effort to lose weight

For subjects with type 2 diabetes at screening the following inclusion criteria apply in addition:

- HbA1c equal to or below 10.0% (86 mmol/mol) as measured by central laboratory at screening

Exclusion Criteria:

Prepubertal subjects (Tanner stage 1)
History of type 1 diabetes
A self-reported (or by parent(s)/legally acceptable representative where applicable) change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)
For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Intervention: Zolpidem
Trial phase: Early Phase 1
ATC code: N05CF02
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.

Zolpidem: Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
Eligibility criteria:
Inclusion Criteria:

Age >=18 years
In-center diagnostic or split night sleep study (PSG)

Exclusion Criteria:

No exclusion criteria
Intervention: Deulinoleate ethyl
Trial phase: Phase 3
SMILES: [2H]C([2H])(/C=C\CCCCC)/C=C\CCCCCCCC(=O)OCC
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 33
Group description: 9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.
Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment

RT001: RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
Eligibility criteria:
Key Inclusion Criteria:

Male or female 12 to 50 years of age
Medical history consistent with the symptoms of FRDA at ≤ 25 years of age
Detection of biallelic pathogenic variants in frataxin gene (FXN)
Ambulatory (with or without assistive device) and capable of performing other assessments/evaluations.
Must be able to walk 25 feet during the timed 1-minute walk

Key Exclusion Criteria:

Received treatment with other experimental therapies within the last 30 days prior to the first dose
Previously participated in the RT001 trial
Refusal to discontinue fish oils or other oil-based supplements for the duration of the study (Screening till last study procedure completed)
History of malignancies (other than basal cell carcinomas)
Inability to complete CPET protocol
Female who is breastfeeding or has a positive pregnancy test
History of uncontrolled diabetes mellitus (Type 1 or 2)
Intervention: Valbenazine
Trial phase: Phase 3
ATC code: N07XX13
SMILES: COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 64
Group description: Capsule, administered orally once daily for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Have a clinical diagnosis of Huntington Disease (HD) with chorea
Be able to walk, with or without the assistance of a person or device
Participants of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently while participating in the study until 30 days (females) or 90 days (males) after the last dose of the study drug
Be able to read and understand English

Exclusion Criteria:

Have a history of previously established therapy with a VMAT2 inhibitor, in the judgement of the investigator
Have difficulty swallowing
Are currently pregnant or breastfeeding
Have a known history of long QT syndrome, cardiac tachyarrhythmia, left bundle-branch block, atrioventricular block, uncontrolled bradyarrhythmia, or heart failure
Have an unstable or serious medical or psychiatric illness
Have a significant risk of suicidal behavior
Have a history of substance dependence or substance (drug) or alcohol abuse, within 1 year of screening
If taking antidepressant therapy, be on a stable regimen
Have received gene therapy at any time
Have received an investigational drug in a clinical study within 30 days of the baseline visit or plan to use such investigational drug (other than valbenazine) during the study
Have had a blood loss ≥550 milliliters (mL) or donated blood within 30 days before the baseline visit
Had a medically significant illness within 30 days before baseline, or any history of neuroleptic malignant syndrome
Intervention: Plasma kallikrein
Trial phase: Phase 4
ATC code: B06AC03
SMILES: CCC(C)C1NC(=O)C(Cc2ccccc2)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C2CSSCC3NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(Cc4ccccc4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CSSCC(NC(=O)C4CCCN4C(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(Cc4ccccc4)NC(=O)C(C)NC(=O)C(NC(=O)C(Cc4ccccc4)NC(=O)C(CO)NC(=O)C(Cc4cnc[nH]4)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C(N)CCC(=O)O)CSSCC(C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)O)C(C)O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC3=O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(C)C(=O)NC(Cc3cnc[nH]3)C(=O)N3CCCC3C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc3c[nH]c4ccccc34)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(CC(N)=O)C(=O)NC(C(C)CC)C(=O)NC(Cc3ccccc3)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(N)=O)C(=O)N2)NC(=O)CNC(=O)CNC(=O)C(Cc2ccc(O)cc2)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
Eligibility criteria:
Inclusion Criteria:

18 years old ≤ age <80 years old; Within 72 hours of onset; Diagnosed as acute cerebral infarction, and confirmed by magnetic resonance imaging as an acute infarct in the unilateral corticospinal tract; The patient's onset muscle strength grade <4; No history of cerebral infarction or residual physical activity disorder; No other intracranial lesions; Patients or their legal representatives voluntarily Sign the informed consent form;

Exclusion Criteria:

Intracranial hemorrhagic disease: cerebral hemorrhage, subarachnoid hemorrhage, etc.; Transient ischemic attack; Intravenous thrombolysis and interventional thrombectomy; Serious physical illness affects limb movement before enrollment ; Apply other drugs with nutritional nerves and regeneration during the study period; Unstable vital signs, severe liver and kidney diseases or malignant tumors; Incomprehensible or incapable of obeying the research procedure or being unable to follow up due to mental illness, cognitive or emotional disorders;
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 22
Group description: Participant received intravenous oxytocin, 10 International Units (IU) on study day 1 or 2
Eligibility criteria:
Inclusion Criteria:

Male or female > 18 and < 66 years of age,
Body Mass Index (BMI) <40
Generally in good health as determined by the Principal Investigator based on prior medical history
Normal blood pressure and resting heart rate without medication

Exclusion Criteria:

Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®
Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk
Women who are pregnant (positive result for serum pregnancy test at screening visit),
Women who are currently nursing or lactating, women that have been pregnant within 2 years.
Neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis.
Previous eye surgery, eye medications, cataracts
Intervention: Benzodiazepine
Trial phase: Phase 2
SMILES: C1=Cc2ccccc2NN=C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: The study population will consist of outpatients receiving OAT for opioid use disorder who are also using BZDs regularly. All participants will receive the same BZD discontinuation protocol.
Eligibility criteria:
Inclusion Criteria:

Age 18 or older
Receiving OAT (methadone or buprenorphine) confirmed by toxicology testing for at least 90 days and on a steady dose for 2 consecutive weeks
Regular BZD use defined by BZD use 3 or more times per week in past month by self-report and positive urine screen at time of recruitment
Provides permission to contact current BZD prescriber if being prescribed BZDs
Speaks English
Wants to discontinue BZD use

Exclusion Criteria:

Pregnant, confirmed by urine pregnancy test
Cognitive impairment, as indicated by a score of < 23 on the Mini Mental Status Exam
Any past month illicit opioid, barbiturate, z-drug, cocaine, unprescribed amphetamine, or synthetic cannabinoid use determined by self-report or urine drug test
Receiving ongoing psychosocial treatment for BZD use disorder
Uncontrolled seizure disorder (i.e. seizure in prior 90 days), or past BZD withdrawal seizure
Current suicidality or homicidality
Current psychotic symptoms
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 125
Group description: normal saline 0.9%
Eligibility criteria:
Inclusion Criteria:

patients 18 to 79 who have undergone a cystoscopy with indwelling double-J ureteral stent placement at Clements University Hospital and are presenting to the office for cystoscopy and stent removal.

Exclusion Criteria:

eGFR <50
any active or history of peptic ulcer disease or GI bleeding
Bleeding disorder, suspected of confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis
Concurrent use of Aspirin 325mg, wafarin, rivaroxaban, apixaban, clopidogrel, or heparin
Allergic reaction to NSAIDs
Concurrent use of other NSAIDs within 24 hours
Pregnancy (ketorolac contraindicated in this population)
Recent myocardial infarction (MI)
Intervention: Ketorolac
Trial phase: Phase 2
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 125
Group description: 30 mg of Ketorolac
Eligibility criteria:
Inclusion Criteria:

patients 18 to 79 who have undergone a cystoscopy with indwelling double-J ureteral stent placement at Clements University Hospital and are presenting to the office for cystoscopy and stent removal.

Exclusion Criteria:

eGFR <50
any active or history of peptic ulcer disease or GI bleeding
Bleeding disorder, suspected of confirmed cerebrovascular bleeding, hemorrhagic diathesis, or incomplete hemostasis
Concurrent use of Aspirin 325mg, wafarin, rivaroxaban, apixaban, clopidogrel, or heparin
Allergic reaction to NSAIDs
Concurrent use of other NSAIDs within 24 hours
Pregnancy (ketorolac contraindicated in this population)
Recent myocardial infarction (MI)
Intervention: Velpatasvir
Trial phase: Phase 3
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Participants received sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) (400/100 mg) tablet orally once daily for up to 12 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Chronic HCV-infected males and non-pregnant/non-lactating females
Treatment-naïve or treatment-experienced individuals
Compensated cirrhosis at Screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 104
Group description: Dexamethasone 4mg, administered intravenously

Dexamethasone 4mg: Dexamethasone 4mg + metoclopramide 10mg, intravenously
Eligibility criteria:
Inclusion Criteria:

Moderate or severe migraine

Exclusion Criteria:

Medication contra-indication
Concern for secondary cause of headache